Pacific Edge (ASX:PEB) Beta: -0.8850 (As of Jun. 26, 2026)


ASX:PEB Pacific Edge Ltd ASX:PEB
42 GF Score
Price A$0.24
GF Value A$0.05
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pacific Edge Beta?

Pacific Edge ASX:PEB -4.00% 42 Beta is -0.8850 as of Jun. 26, 2026. GuruFocus rates ASX:PEB with a GF Score™ of 42/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Pacific Edge's Beta is -0.8850.


Pacific Edge  (ASX:PEB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Pacific Edge Beta Related Terms


Pacific Edge Beta Historical Data

* Premium members only.

The historical data trend for Pacific Edge's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Edge Beta Chart

Pacific Edge Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.31 -0.55

Pacific Edge Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.08 -0.31 -0.96 -0.55

ASX:PEB vs TMO, DHR, IDXX: Beta Comparison

For the Diagnostics & Research subindustry, Pacific Edge's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Edge Beta vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Beta distribution charts can be found below:

* The bar in red indicates where Pacific Edge's Beta falls into.


ASX:PEB
42GF Score
Pacific Edge Ltd ASX:PEB
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Edge Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.8850 mean?
Pacific Edge (ASX:PEB) has a Beta of -0.8850 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pacific Edge and its competitors.
Is Pacific Edge's Beta too high?
Pacific Edge's current Beta is -0.8850. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Beta compare to TMO and DHR?
Pacific Edge's Beta of -0.8850 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Diagnostics & Research company?
A good Beta depends on the Medical Diagnostics & Research industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pacific Edge and its competitors. Pacific Edge's current Beta is -0.8850. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.24 — trading 380% above its estimated fair value. The current Beta is -0.8850. Pacific Edge's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Beta is -0.8850 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.24 is trading 380% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • Beta: -0.8850
  • GF Value™: A$0.05 vs. price of A$0.24 (380% above fair value)
  • GF Score™: 42/100 with 8 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score

Get the complete analysis for ASX:PEB

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.24
Price
A$0.05
GF Value